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Background: In Africa, tuberculosis is generally regarded as persisting as one of the
most devastating infectious diseases. The pediatric population is particularly vulnerable,
with infection of the brain in the form of tuberculous meningitis (TBM) being the most
severe manifestation. TBM is often difficult to diagnose in its early stages because of
its non-specific clinical presentation. Of particular concern is that late diagnosis, and
subsequent delayed treatment, leads to high risk of long-term neurological sequelae,
and even death. Using advanced technology and scientific expertise, we are intent on
further describing the biochemistry behind this devastating neuroinflammatory disease,
with the goal of improving upon its early diagnosis.
Method: We used the highly sensitive analytical platform of gas chromatography-mass
spectrometry (GC-MS) to analyze amino acid profiles of cerebrospinal fluid (CSF)
collected from a cohort of 33 South African pediatric TBM cases, compared to 34
controls.
Results: Through the use of a stringent quality assurance procedure and various
statistical techniques, we were able to confidently identify five amino acids as being
significantly elevated in TBM cases, namely, alanine, asparagine, glycine, lysine,
and proline. We found also in an earlier untargeted metabolomics investigation that
alanine can be attributed to increased CSF lactate levels, and lysine as a marker of
lipid peroxidation. Alanine, like glycine, is an inhibitory neurotransmitter in the brain.
Asparagine, as with proline, is linked to the glutamate-glutamine cycle. Asparagine is
associated with the removal of increased nitrites in the brain, whereas elevated proline
coincides with the classic biochemical marker of increased CSF protein in TBM. All five
discriminatory amino acids are linked to ammonia due to increased nitrites in TBM.
Conclusion: A large amount of untapped biochemical information is present in CSF of
TBM cases, of which amino acid profiling through GC-MS has potential in aiding in earlier
diagnosis, and hence crucial earlier treatment.
Keywords: gas chromatography-mass spectrometry (GC-MS), tuberculous meningitis (TBM), pediatric,
cerebrospinal fluid (CSF), amino acid profiling
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INTRODUCTION
Tuberculosis (TB), caused byMycobacterium tuberculosis (Mtb),
is an ancient, persistent disease that remains a huge, deadly issue
to this day. According to the World Health Organization (WHO,
2016), during 2015 there were an estimated 10.4 million new
(incident) TB cases worldwide, of which 5.9 million were men,
3.5 million were women, and 1 million were of children. Six
countries accounted for 60% of the new cases: India, Indonesia,
China, Nigeria, Pakistan, and South Africa. An estimated 1.8
million people died from TB in 2015, with the mortality of
cohorts of more than 100 individuals with extreme drug-resistant
(XDR) TB being highest (>40%) in India and South Africa. The
incidence of TB in South Africa (population 55 million) for 2015
was estimated to be 454,000 (294,000–649,000) individuals, of
whom 33,000 (21,000–44,000) were children (<14 years of age).
Hence, South Africa is one of the worst-stricken regions under
the scourge of the M. tuberculosis bacillus, which depends on
humans for its transmission.
TB is most commonly known in its pulmonary form;
however, Mtb is not only localized in the lungs but, because
of the systematic spread of the tubercule bacilli, can lead to
extrapulmonary forms. A preferred site for Mtb—with high
blood flow and oxygen content—is the brain; the pathogen
is capable of crossing the blood-brain barrier and entering
the meninges, which consist of three membranes between
the skull and the brain. Infection within the meninges by
Mtb leads to tuberculous meningitis (TBM)—the most severe
manifestation of TB. The pathology that occurs in the central
nervous system (CNS) is similar to that of its pulmonary
type, in that lesions (turberculomas) form and can rupture—
releasing inflammatory markers. CNS-TB represents up to an
estimated 10% of all forms of extra-pulmonary TB (and 1%
of total TB) cases (Rock et al., 2005; Bhigjee et al., 2007;
Cherian and Thomas, 2011), of which TBM is the principal
manifestation.
The gold standard for diagnosis of TBM requires collection of
cerebrospinal fluid (CSF), typically through a lumbar puncture.
In 2010, Marais et al. proposed a uniform research case
definition of TBM based on CSF: (1) TBM could be classified
as “definite” when CSF demonstrated acid-fast bacilli on
microscopy, a positive Mtb culture and/or passed a positive CSF
Mtb commercial nucleic acid amplification test in an individual
with symptoms or signs suggestive of the disease. (2) TBM could
be classified as “probable” according to a scoring system based
on clinical, CSF and neuroimaging criteria, as well as evidence of
extraneural TB. In practice, however, TBM is difficult to diagnose
in its early stages due to its non-specific clinical presentation. A
particular concern is that late diagnosis, and subsequent delayed
treatment, leads to high risk of long-term neurological sequelae,
and even death.
The two primary biochemical markers currently considered
for differential diagnosis of TBM are CSF protein and glucose
levels (Solomons et al., 2015). Protein levels are defined as
being either elevated—greater than 40 mg/dl (lower cut-off), or
significantly elevated—greater than 100 mg/dl (higher cut-off)
(Youssef et al., 2006; Hristea et al., 2012). Depressed glucose is
defined as <2.2 mmol/l as an absolute value, or relatively as <0.5
CSF:blood glucose ratio as standardized cut-off values (Marais
et al., 2010; Solomons et al., 2015).
Our group recently conducted an untargeted proton magnetic
resonance (1H-NMR) metabolomics study on CSF from 17
pediatric cases with TBM (Mason et al., 2015), which revealed
lowered glucose (as expected) and highly elevated lactate as the
most defining biochemical markers of the disease, along with
perturbed amino acids. The presence of highly elevated CSF
lactate was further examined (Mason et al., 2016) and shown
to be produced only by the host (with zero contribution from
invading Mtb)—an interesting outcome in that the human brain
mass produces lactate during a neuroinflammatory disease such
as TBM. Indeed, CSF lactate has gained much attention recently
in neuroenergetics (Mason, 2017), perhaps as a consequence
of being an especially important biochemical marker of Mtb
infection. Interestingly, the most prominent CSF metabolites
identified by our untargeted 1H-NMR metabolomics study
as indicators of TBM were also derived in a completely
independent study using exactly the same NMR data set and
a novel nonparametric classification system (van Reenen et al.,
2016)—a method of mathematical modelling for deductive
verification of the AMLS (astrocyte–microglia lactate shuttle)
hypothesis.
A secondary CSF biosignature of TBM revealed by our
previous untargeted NMR metabolomics study consisted largely
of perturbed amino acids—alanine, branched-chain amino acids
(leucine, isoleucine, and valine), and lysine. These gluconeogenic
amino acids, together with ketones, were postulated to be
involved in directing (through shuttling mechanisms) CSF
lactate, produced by glycolysis in astrocytes, from neurons
preferentially into activated microglia in an attempt to aid the
eradication of invadingMtb bacilli. Collectively, this biosignature
led us to postulate the astrocyte–microglia lactate shuttle. Here,
we now report on a more detailed targeted metabolomics study
on the amino acid profiles in TBM from a larger collection of CSF
samples.
Perturbations in amino acids in TBM cases are not a
novel discovery as they have been observed previously in
biochemical studies. In 1981, Corston et al. examined eleven
viral meningitis and four TBM cases and reported that total
amino acid concentrations in CSF were markedly higher in
TBM than in viral meningitis. In 1998, Qureshi et al. compared
several neurochemical markers in CSF between 11 cases of
viral meningitis and 12 of TBM. These authors, using high-
pressure liquid chromatography, reported significantly increased
aspartic acid, glutamic acid, GABA, glycine, and tryptophan in
all cases, whereas only TBM cases exhibited significantly elevated
phenylalanine, arginine, and homocysteine. From their results,
Qureshi et al. postulated that inflammatory changes in meninges
may interfere with amino acid transport across the blood–brain
barrier, and proposed several therapeutic approaches. These
earlier results on perturbed amino acids in TBM were, however,
based on small sample sizes.
Here, we present the first report on a detailed amino
acid profiling study of CSF obtained from a cohort of 33
TBM pediatric cases, compared to 34 controls. The method of
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analysis used was the sensitive platform of gas chromatography-
mass spectrometry (GC-MS). Based upon stringent statistical
analyses and quality control measures, five amino acids—alanine,
asparagine, glycine, lysine, and proline—were identified as being
significantly increased in our group of TBM patients, of which
we discuss the biological implications in the context of TBM.
These observations justify the need for a comprehensive study
on biochemical markers for TBM to be validated in a large-scale
follow-up investigation.
METHODS
Sampling
This study was focused on a pediatric group with suspected
TBM from the region surrounding Tygerberg Hospital in the
Western Cape province of South Africa—an area endemic for
TB. A specialized pediatric neurology unit within the hospital
focuses on diagnosing and treating cases of TBM in the region.
For the purposes of this study, a diagnosis of TBM was based
on the uniform research case definition of Marais et al. (2010).
Only children (>3 months and <13 years of age) with “definite”
and “probable” TBM were included in the experimental patient
group (n = 33). Our controls (n = 34) were age-matched
pediatric patients suspected of meningitis, but later confirmed to
bemeningitis negative. Detailed clinical information on the study
cohort is included in Supplementary Information (Table S1).
Informed and written consent was obtained from each patient’s
caregiver and assent if the child was older than 7 years and
competent to do so. The study was approved by the Human
Research Ethics Committee of Stellenbosch University, South
Africa (study no. N11/01/006).
Gas Chromatography-Mass Spectrometry
Each CSF sample was filtered to remove bacteria—to ensure
safety while handling—as well as for the removal of proteins and
other macromolecules. Filtration was done using the Sartorius
Centrisart R©1 10-kDa centrifugal unit by centrifugation of CSF
samples for 15 min at 3,000 rpm. Samples were prepared using
the commercially available EZ:faastTM analysis kit (Phenomenex)
for the analysis of free (physiological) amino acids by GC-MS.
See SI for full details on sample preparation, as well as instrument
details.
In conjunction with the CSF samples, several external quality
control (EQ) samples were included—commercial lyophilized
human serum samples spiked with known concentrations of
amino acids (Fowler et al., 2008). Calibration standard (CS)
samples—commercial standard mixtures of amino acids as part
of the EZ:faastTM analysis kit, were also included. The CS samples
were used to quantify each block of samples (e.g., a calibration
curve was created using CS2 and CS3 and this curve was used to
quantify samples in block À, CS5 and CS6 were used to calibrate
EQ3, and so on). Each block of samples consisted of either seven
or eight randomized experimental samples, with a total of 10
blocks. The experimental run was as follows:
Blank||CS1|EQ1A|EQ1B|CS2|À|CS3|EQ2|CS4|Á|CS5|EQ3|
CS6|Â|CS7|EQ4|CS8|Ã|CS9|EQ5|CS10|Ä|CS11|EQ6|CS12|Å|
CS13|EQ7|CS14|Æ|CS15|EQ8|CS16|Ç|CS17|EQ9|CS18|È|CS19|
EQ10|CS20|É|CS21|EQ11|EQ1C|EQ1D|CS22||end
Data Analysis
The GC-MS data were deconvoluted, identified and annotated
using NIST spectral libraries, and quantified using AMDIS
(Automated Mass Spectral Deconvolution and Identification
System). These data were amalgamated into one (n × m)
data matrix composed of m amino acid identities and n
sample identities. Each entry consisted of a concentration
value calculated in micromoles per liter (µmol/l). Statistical
analyses were performed using The Unscrambler R© X (V10.4,
CAMO software AS, Norway) and the online metabolomics
suite, Metaboanalyst 3.0 (www.metaboanalyst.ca) (Xia et al.,
2015). Unsupervised principal component analysis (PCA) and
Hotelling’s T2-test, with a confidence level of 95%, were used to
remove case outliers—in two TBM and two control cases. The
final data matrix consisted of 29 amino acids and 67 cases (TBM
= 33, control = 34). Shifted log transformation and autoscaling
was applied for multivariate analyses.
RESULTS
Data Quality Assessment
The entire experiment was run as one batch to ensure no
batch effects. EQ samples were analyzed at equal intervals
throughout the run to assess the quality of the GC-MS data
produced. The first EQ (EQ1) was injected four times—twice
at the start (EQ1A and EQ1B) and twice at the end (EQ1C
and EQ1D) of the run—to assess the stability of each analyzed
amino acid over time as the entire run time of the experiment
was approximately 22 h. Each sample was pre-loaded onto
an autosampler at room temperature. The means of the first
two repeat EQ1 samples were compared with those of the
last two repeat EQ1 samples. The results of the data quality
assessment are given in the Table S2. Overall, the derivatized
samples remained stable while within the autosampler. The only
significantly notable amino acid concentration differences were
those of cystathionine, which dropped by 42%, and of cystine and
leucine, which increased by 34 and 40%, respectively. However,
manual inspection of the data showed that the first value of
cystine (EQ1A) was extremely low (an outlier); removal of this
outlier revealed that cystine changed by only 3.42% over the
entire run, indicating that the associated increase was a false
assessment. By examining the EQ samples over the complete run
and comparing them with ERNDIM consensus values (Fowler
et al., 2008), we found that asparagine and cystine fell within
the expected 95% confidence intervals—indicating very good
reliability (indicated by the green section in Table S2). The amino
acids with poor performance (see red section in Table S2) were
glutamine, leucine, ornithine, tryptophan, and valine; glutamine
demonstrated the greatest variability over the experimental run.
The remaining 15 amino acids (alanine, alpha-aminobutyric acid,
aspartic acid, cystathionine, glutamic acid, glycine, histidine,
isoleucine, lysine, methionine, phenylalanine, proline, serine,
threonine, and tyrosine) fell within the lab expected ranges of
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FIGURE 1 | (Left) principal component analysis (PCA) scores plot (top) and corresponding loadings (bottom) of the various amino acids identified in the TBM and
control cases. (Right) Partial least squares discriminant analysis (PLS-DA) scores plot (top) with corresponding loadings (bottom) indicating important discriminatory
(circled) variables.
the ERNDIM consensus value and therefore had good reliability
(highlighted in yellow in Table S2).
Identification of the Important
Discriminatory Amino Acids
Figure 1 illustrates the application of unsupervised PCA and
supervised partial least squares discriminant analysis (PLS-DA).
Based on these analyses, the two groups can be differentiated
based purely on amino acids, but not completely separated.
Within the PLS-DA correlation loadings plot there are 11
amino acids (circled on the figure)—identified as being the most
important discriminatory metabolites based upon leave-one-out
cross-validation (R2 = 63.9%, Q2 = 55.3%). These 11 amino
acids are: alanine, alpha-aminobutyric acid, asparagine, glycine,
hydroxylysine, lysine, ornithine, proline, serine, threonine, and
valine. Soft independent modeling of class analogy (SIMCA)
analysis was performed (Figure 2) based on the PLS-DA model,
indicating three misclassifications for the TBM group. Hence,
based on the prediction value of our PLS-DA model, three TBM
cases were misclassified as control cases. The strength of this
model is that there are no false positive classifications.
Univariate statistical analyses were also performed using
Mann–Whitney p-values and fold changes. The results of these
univariate analyses are illustrated in the volcano plot (Figure 3).
Amino acids with significant values (Mann–Whitney p < 0.05
and fold change> 1.0) are indicated, namely, alanine, asparagine,
glycine, histidine, lysine, proline, hydroxylysine, and valine.
Based on the combination of both multivariate and univariate
analyses, therefore, themost important, common, discriminatory
amino acids of the control and TBM cases are: alanine (TBM: 77.3
± 52 µmol/l, control: 25 ± 9.5 µmol/l, ref.1: 11–53.5 µmol/l);
asparagine (TBM: 19.9 ± 14 µmol/l, control: 5.3 ± 1.7 µmol/l,
1Reference ranges given for children (0–10 years) obtained from the Human
Metabolome Database, based upon values reported values from the University of
British Columbia, B.C.’s Children’s Hospital Biochemical Genetics Lab.
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FIGURE 2 | SIMCA analysis of the PLS-DA model indicating only three misclassifications for the TBM group—three false negatives predicted. Reference numbers
with prefix T indicate TBM; similarly, prefix C indicates control.
ref.: 4–10 µmol/l); glycine (TBM: 58.2 ± 31.7 µmol/l, control:
24.4 ± 1.4 µmol/l, ref.: 1–10 µmol/l); lysine (TBM: 36.5 ±
25.2 µmol/l, control: 14.5 ±5.2 µmol/l, ref.: 6–37 µmol/l); and
proline (TBM: 24.3 ± 25.8 µmol/l, control: 1.8 ± 0.5 µmol/l,
ref.: 0–3 µmol/l) (shown as box plots in Figure 4). From the
quality control assessment, these five amino acids indicate good
reliability and hence are confidently identified as the important
discriminatory variables for this study. It is important to note that
hydroxylysine and valine were present as important amino acids
but valine failed in the EQ reliability test and hydroxylysine was
not part of the quality control assessment, hence neither of the
last two was included in the discussion.
DISCUSSION
The present targeted GC-MS data correspond with our
previous untargeted NMR study (Mason et al., 2015), which
highlighted alanine, lysine and branched-chain amino acids
as important as well as other, non-amino acid metabolites.
Similar to our earlier untargeted NMR study, the five
discriminatory metabolites identified here are associated with
perturbed energy metabolism. As previously underscored in a
review of lactate shuttles (Mason, 2017): “Understanding brain
energy metabolism—neuroenergetics—is becoming increasingly
important as it can be identified repeatedly as the source
of neurological perturbations.” Here, alanine is closely linked
FIGURE 3 | Volcano plot indicating amino acids in TBM-infected CSF based
on univariate analyses—y-axis: Mann–Whitney p-value, x-axis: fold change.
Significant amino acids with p < 0.05 and fold change > |1.0| are labeled;
namely: alanine, asparagine, glycine, histidine, hydroxylysine, lysine, proline,
and valine.
to lactate and the associated shuttling systems. The data of
the study presented here further highlight the importance of
understanding neuroenergetics when the brain is in crisis. Also,
alanine, like glycine, is an inhibitory neurotransmitter in the
brain. Furthermore, as discussed in Mason et al. (2015), elevated
lysine seen in CSF from TBM patients has been associated
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FIGURE 4 | Box plots of the five most important amino acids in CSF that discriminate between TBM and controls. Y-axis indicates CSF concentration (µmol/l);©
indicates outliers.
with mental retardation and in other motor neuron diseases
(Shaw et al., 1995); it has also been shown to form adducts
with other compounds, such as acrolein–lysine, a marker of
lipid peroxidation in childhood meningitis (Tsukahara et al.,
2002).
Asparagine, synthesized from central metabolic pathway
intermediates, has the precursor oxaloacetic acid—an
intermediate of the energy (Krebs) cycle. Asparagine is
important in the metabolism of toxic ammonia in the body
through the action of asparagine synthase, which attaches
ammonia to aspartic acid in an amidation reaction. According
to Qureshi et al. (1998), nitrites are significantly elevated in
TBM cases. Hence, increased nitrogen excretion is expected
in TBM patients in the form of elevated ammonia. This
nitrogen excretion by-product is thus expected to be removed
from the brain with asparagine as the carrier. Of special
note, all five identified discriminatory amino acids are either
directly or indirectly linked to ammonia. Asparagine is also
involved in the glutamate-glutamine cycle, in which the enzyme
asparagine synthetase produces asparagine, AMP, glutamate,
and pyrophosphate from aspartate, glutamine and ATP. In
the asparagine synthetase reaction, ATP is used to activate
aspartate, forming beta-aspartyl-AMP. Glutamine donates an
ammonium group, which reacts with beta-aspartyl-AMP to
form asparagine and free AMP. Although glutamic acid and
glutamine were not identified as significantly perturbed in
this study, it can be postulated that a significant increase in
TABLE 1 | Summary of concentrations of alanine, asparagine, glycine, lysine, and
proline as reported for TBM in this study, compared to previously reported values
for Alzheimer’s and schizophrenia (concentrations given as µmol/l).
Alzheimer’s
(Fonteh et al.,
2007)
Schizophrenia
(Do et al., 1995)
This study (TBM)
Alanine 4.04 ± 0.57 77.3 ± 52
Asparagine 1.77 ± 0.16 6.01 ± 0.65 19.9 ± 14
Glycine 0.28 ± 0.12 4.50 ± 0.75 58.2 ± 31.7
Lysine 44.6 ± 10.8 36.5 ± 25.2
Proline 0.68 ± 0.35 24.3 ± 25.8
asparagine can still be linked to a slightly perturbed glutamate-
glutamine cycle in conjunction with increased ammonia—being
particularly toxic in the brain as it alters neurotransmitter
homeostasis. This postulate can be extended to proline, which
is biosynthetically derived from glutamate and its immediate
precursor, 1-pyrrole-5-carboxylate. Proline is a proteinogenic
amino acid and is incorporated into proteins by prolyl-tRNA.
Since elevated protein levels in CSF is a classic hallmark of
TBM, it is not surprising to find proline at elevated levels.
Proline is, however, used mainly for collagen formation
and is important in maintaining good health in muscle,
joints, and tendons. Perturbed levels of proline are normally
associated with degenerative arthritis. Increased turnover of
proline was, however, found in probable Alzheimer’s disease
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cases (Fonteh et al., 2007) without arthritis, possibly reflecting
increased brain degeneration.
In a study on the change in CSF amino acid profiles following
an acute tonic-clonic seizure, Rainesalo et al. (2004) measured
amino acid levels in CSF before and after a seizure. Rainesalo
et al. reported an increase in alanine (21.5 ± 1.2 to 23.1 ±
1.4 µmol/l), asparagine (6.2 ± 0.3 to 7.7 ± 0.5 µmol/l), and
glycine (5.8 ± 0.5 to 7.4 ± 0.7 µmol/l), and a slight decrease
in lysine (17.7 ± 0.9 to 17.1 ± 0.9 µmol/l)—none statistically
significant. Understandably, an acute tonic-clonic seizure (full
body, grand mal, seizure) is a severe physiological response, yet
Rainesalo et al. reported only slight changes in most amino acids
(significant changes in taurine, ornithine, and phenylalanine).
Table 1 compares the five discriminatory amino acids identified
in our study, as being most important in TBM, with those of
studies of a chronic neuroinflammatory disease, Alzheimer’s, and
a psychiatric disorder, schizophrenia. This comparison indicates
that these particular five amino acids occur at levels 2–10
times greater in TBM, further highlighting the severity of the
pathophysiological condition of this disease.
CONCLUDING REMARKS
In this study, we used the sensitive method of GC-MS to
profile the amino acids of CSF collected from pediatric patients
classified as being “definite” or “probable” cases of TBM. Through
stringent quality assessment measures and statistical analyses
(univariate and multivariate) we identified five amino acids in
our experimental TBM patients as being reliable and having
strong discriminatory power. The concentrations of the amino
acidmarkers of TBMhere occur at levels many times greater than
other neuropathological conditions, highlighting the severity of
TBM. Our latest observations justify the need for more detailed
studies on biochemical markers of TBM to be validated in larger-
scale, and preferably multi-institutional, follow-up investigations
as amino acid profiling has potential in aiding in earlier diagnosis,
and hence crucial earlier treatment of TBM.
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